Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Prednisolone-induced Hepatic Insulin Resistance
NCT04315350Terminated
- Sponsor
- Gentofte Hospital
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of curcumin in insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Gentofte Hospital. Primary endpoint: Homeostatic Model Assessment of Insulin Resistance. Started Dec 2019; status: terminated.
02
Drugs
curcumin
03
Conditions
insulin resistance (IR)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04315350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315350.